Chest X-Rays May Miss Pulmonary Metastases in T1a RCC Patients
Findings in patients treated for T1a renal cell carcinoma followed with X-ray surveillance.
Diagnosis & Disease Information
Cabozantinib Shows Superiority in Treating Advanced mRCC
The drug significantly improves overall and progression-free survival compared with everolimus, researchers report.
Early Tumor Shrinkage Predicts mRCC Treatment Outcomes
The optimal tumor shrinkage threshold for predicting overall and progression-free survival is 10%, researchers concluded.
AKI After RCC Surgery On the Rise
Nearly 6% of patients who underwent partial or radical nephrectomy between 1998 and 2010 developed AKI.
Survival Advantage Confirmed for Nephrectomy in mRCC
About 25% of patients who present with metastatic renal cancer will undergo nephrectomy after diagnosis.
Cytoreductive Nephrectomy Benefits Select mRCC Patients Taking TT
Among patients treated with targeted therapy, overall survival was 17.1 months for CN recipients vs 7.7 months for those without CN.
Renal Transplant Patients At Higher Risk of Papillary RCC
Only this histologic variant occurs at a significantly higher incidence in renal allograft recipients than the non-transplant population.
More mRCC Patients Receiving Treatment
Cytoreductive nephrectomy (CN) use remained stable in the targeted therapy era, but more patients are receiving a combination of CN and systemic therapy.
Partial Nephrectomy Feasible for T3a Renal Cell Carcinoma
Study shows no meaningful differences between partial and radical nephrectomy in 5-year rates of local recurrence or cancer-related death.
Positive Margins After Partial Nephrectomy Raises Death Risk
Positive surgical margins are associated with a significant 34% increased risk of all-cause mortality.
- Loading...
Loading...
Next post in Kidney Cancer
Loading... 
Loading...